Rallybio Corporation
RLYBHealthcare|Biotechnology|US
$15.75
+0.06 (+0.38%)
DCF Value
$10.28
Tangible Book / Share
$16.15
Graham Number
$41.29
Cash / Share
$15.87
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06435845 Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization | Fetal and Neonatal Alloimmune Thrombocytopenia | P2 | Terminated | 1 | Open-label | Anti-(integrin beta-3) human monoclonal antibody |
| NCT06797375 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants | Hematologic Diseases, Autoimmune Diseases | P1 | Completed | 16 | RCT, Double-blind | RLYB116 for Injection |
| NCT05345561 Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia | Fetal and Neonatal Alloimmune Thrombocytopenia | Completed | 14,390 | — | — |